PT  - JOURNAL ARTICLE
AU  - Eberhardt, Ruth Y.
AU  - Wright, Caroline F.
AU  - FitzPatrick, David R.
AU  - Hurles, Matthew E.
AU  - Firth, Helen V.
TI  - Detection of mosaic chromosomal alterations in children with severe developmental disorders recruited to the DDD study
AID  - 10.1101/2022.03.28.22273024
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.03.28.22273024
4099  - http://medrxiv.org/content/early/2022/04/07/2022.03.28.22273024.short
4100  - http://medrxiv.org/content/early/2022/04/07/2022.03.28.22273024.full
AB  - Purpose Structural mosaicism has been previously implicated in developmental disorders. We aim to identify rare mosaic chromosomal alterations (MCAs) in probands with severe undiagnosed developmental disorders.Methods We identified MCAs in SNP array data from 12,530 probands in the Deciphering Developmental Disorders (DDD) study using MoChA.Results We found 61 MCAs in 57 probands, many of these were tissue specific. In 23/26 (88.5%) cases for which the MCA was detected in saliva where blood was also available for analysis, the MCA could not be detected in blood. The MCAs included 20 polysomies, comprising either one arm of a chromosome or a whole chromosome, for which we were able to show the timing of the error (25% mitosis, 40% meiosis I, 35% meiosis II). Only 2/57 (3.5%) of the probands in whom we found MCAs had another likely genetic diagnosis identified by whole exome sequencing, despite an overall diagnostic yield of ∼40% across the cohort.Conclusion Our results show that identification of MCAs provides candidate diagnoses for previously undiagnosed patients with developmental disorders, potentially explaining ∼0.45% of cases in the DDD study. Nearly 90% of these MCAs would have remained undetected by analysing DNA from blood and no other tissue.Competing Interest StatementM.E.H. is a co-founder and non-executive director of Congenica Ltd and an advisor to Astra Zeneca. Funding StatementThe DDD study presents independent research commissioned by the Health Innovation Challenge Fund [grant number HICF-1009-003]. This study makes use of DECIPHER (http://decipher.genomics.org), which is funded by Wellcome. See Nature PMID: 25533962 or www.ddduk.org/access.html for full acknowledgement. This research was funded in part by the Wellcome grant [206194]. HF receives support from Wellcome grant 200990/A/16/ZAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study has UK Research Ethics Committee approval (10/H0305/83, granted by the Cambridge South Research Ethics Committee and GEN/284/12, granted by the Republic of Ireland Research Ethics Committee).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesDiagnostic variants and phenotypes for probands included in this study are available via the DECIPHER database (https://deciphergenomics.org). Genotype array data is available in EGA. https://deciphergenomics.org